Redcare Pharmacy Shares Stage Impressive Recovery

The Dutch e-pharmacy pioneer Redcare Pharmacy has demonstrated a remarkable turnaround, with its shares surging following months of downward pressure. Investors are now questioning whether this signals a temporary rally or the beginning of a sustained recovery for the company.

Strong Q3 Performance and Leadership Transition

The third quarter revealed a dramatic resurgence in Redcare’s German prescription business, a development that appears to be the primary catalyst for the positive shift. Prescription revenue in Germany soared by an impressive 82.1%, reaching €126 million. This performance marks a significant reversal after two consecutive quarters of declining prescription figures.

CEO Olaf Heinrich highlighted the company’s robust third-quarter momentum, noting “particularly strong double-digit quarterly growth rates in the German prescription segment.” The quarterly gains themselves doubled compared to the previous quarter, rising from €6 million to €12 million.

Alongside these strong financial results, a key leadership change is underway. Chief Financial Officer Jasper Eenhorst will be departing the company at the end of the year. Analysts from Jefferies have interpreted this move as a strategic step by the company to counter prevailing negative market sentiment.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy NV?

International Growth and Customer Metrics

While the German market showed explosive growth, Redcare’s international operations also posted solid gains. The international division, which includes Belgium, Italy, France, and the Netherlands, saw revenue increase by 25.4% to €132 million. Across the entire DACH region, overall sales climbed 25.2% to €587 million.

The company continued to expand its customer base, adding 200,000 new customers to reach a total of 13.7 million. Although this growth was more moderate than in the preceding quarter, it was accompanied by a notable improvement in customer satisfaction, with the Net Promoter Score rising to over 70 points.

Outlook and Sustainability Questions

Despite the management transition, the company’s financial guidance remains steady. Redcare has reaffirmed its full-year forecast, maintaining its target of at least €500 million in prescription revenue. The company anticipates additional support from the seasonal boost typically provided by fourth-quarter holiday sales.

The critical question for investors now centers on sustainability. Can Redcare maintain this impressive momentum through the final quarter? The upcoming full quarterly results, scheduled for release on October 29, are highly anticipated, as they will provide clearer evidence of whether this recovery represents the long-awaited turning point for the e-pharmacy leader.